伊伐布雷定治疗慢性心力衰竭临床疗效Meta分析

发布时间：2018-02-15 19:37

本文关键词： 心力衰竭伊伐布雷定 Meta分析　出处：《中国循环杂志》2017年10期 　论文类型：期刊论文

【摘要】：目的:系统评价伊伐布雷定治疗慢性心力衰竭的临床疗效。方法:计算机检索Pub Med,Conchrane Library,EMbase,中国生物医学数据库(CBM),中国知网(CNKI),万方数据库,检索日期从建库至2016-10。纳入伊伐布雷定治疗慢性心力衰竭的随机对照研究,并采用Revman 5.2软件进行Meta分析。结果:最终纳入12篇文献,均为英文文献,实验组807例,对照组800例。Meta分析显示:与对照组相比,实验组左心室射血分数较高(MD=2.68,95%CI:1.85~3.50,P0.00001),左心室舒张末容积(MD=-5.78,95%CI:-9.79~-1.76,P=0.005)和左心室收缩末容积降低(MD=-8.91,95%CI:-11.23~-6.59,P0.00001);实验组收缩压(MD=6.02,95%CI:-0.80~12.84,P=0.08)和舒张压(MD=3.64,95%CI:-0.48~7.77,P=0.08)与对照组相比差异均无统计学意义;实验组N末端B型利钠肽原(NT-pro BNP)与对照组相比显著降低(MD=-109.22,95%CI:-126.42~-92.01,P0.00001)。结论:伊伐布雷定能改善慢性心力衰竭室重构,但对血压无明显影响。其长期疗效和安全性仍需高质量的随机对照研究及循证医学的证实。
[Abstract]:Objective: to evaluate the clinical efficacy of Ifabradine in the treatment of chronic heart failure (CHF). Methods: a computerized search was conducted for Pub Medchrane Library EMbase, China Biomedical Database, CNKIN, Wanfang database. The retrieval date was from the establishment of the library to 2016-10.The randomized controlled study on the treatment of chronic heart failure with Ifabradine was carried out, and the Meta analysis was performed with Revman 5.2 software. Results: 12 articles were included, all of which were in English, and 807 cases in the experimental group were included in the study group. Meta-analysis of 800 cases in the control group: compared with the control group, The left ventricular ejection fraction (LVEF) in the experimental group was higher than that in the control group (MD-2.68 ~ 95CI: 1.85: 3.50) and MD-5.7895% (MD-5.7895), and the decrease of the left ventricular end-systolic volume (MD-8.91-95CIU -11.23-6.5CU P0.00001). There was no significant difference between the experimental group and the control group in systolic pressure (MD6.0295) and diastolic volume (MD-3.695 CI-0.487.77P0.08). There was no significant difference between the experimental group and the control group in systolic blood pressure (MD6.02CI-0.80 12.84P0.08) and diastolic pressure (3.64995 CI-0.487.77.7P0.08) in comparison with the control group (P 0.001); the left ventricular ejection fraction (LVEF) in the experimental group was higher than that in the control group (P 0.001). There was no significant difference between the experimental group and the control group. Compared with the control group, the N-terminal B-type natriuretic peptide (NT-pro BNPs) of the experimental group significantly decreased MD-109.22 / 95 CI-1: 126.42U -92.01g P0.000010.Conclusion: Ivalburetine can improve the ventricular remodeling of chronic heart failure. But there is no significant effect on blood pressure. The long-term efficacy and safety still need high quality randomized controlled study and evidence-based medicine.
【作者单位】：浙江中医药大学第二临床医学院;浙江中医药大学附属第二医院心内科;
【基金】：基金项目:浙江省中医药(中西医结合)重点学科建设(2012-XK-A16)
【分类号】：R541.6

【相似文献】